```
RESULT 8
AAR28869
ID AAR28869 standard; peptide; 31 AA.
XX
AC AAR28869;
XX
DT 25-MAR-2003 (revised)
DT 23-MAR-1993 (first entry)
XX
DE High affinity macrophage mannose receptor ligand compound #7.
XX
KW glycopeptide; mannose; mannosylated; glycosylated; mannose receptor;
KW macrophages; monocytes; destroy; cytotoxicity; label; image; alter;
KW macrophage processing of antigen; MHC restriction; inflammation;
KW inflammatory diseases; macrophage secretory products; Crohn's disease;
KW legionnaires disease; mononuclear phagocytes; HIV; AIDS;
KW lysosomal storage diseases; Gaucher's disease; asthma;
KW alveolar macrophages metastasis; systemic macrophages; deliver;
KW antigenic peptides; prevent transplant rejection; organ transplantation;
KW antitumour agents; cancer; toxins.
XX
OS Synthetic.
XX
FH Kev
               Location/Qualifiers
FT Modified-site 1
FT
             /note= "opt may have mannose, fucose, glucose or N-Ac-
FT
             glucosamine. May also have non interfering substits."
FT Modified-site 3
             /note= "opt may have mannose, fucose, glucose or N-Ac-
FT
FT
             glucosamine, "
FT Modified-site 5
FT
             /note= "opt may have mannose, fucose, glucose or N-Ac-
FT
             glucosamine, "
FT Modified-site 7
FT
             /note= "opt may have mannose, fucose, glucose or N-Ac-
             glucosamine. "
FT
FT Modified-site 9
FT
             /note= "opt may have mannose, fucose, glucose or N-Ac-
FΤ
             glucosamine. "
FT Modified-site 11
FT
             /note= "opt may have mannose, fucose, glucose or N-Ac-
FT
             glucosamine. "
FT Modified-site 13
FT
             /note= "opt may have mannose, fucose, glucose or N-Ac-
FT
             glucosamine. "
```

```
FT Modified-site 15
FT
             /note= "opt may have mannose, fucose, glucose or N-Ac-
FT
             glucosamine. "
FT Modified-site 17
FT
             /note= "opt may have mannose, fucose, glucose or N-Ac-
FT
             glucosamine. "
FT Modified-site 19
FT
             /note= "opt may have mannose, fucose, glucose or N-Ac-
FT
             glucosamine. "
FT Modified-site 21
FT
             /note= "opt may have mannose, fucose, glucose or N-Ac-
FT
             glucosamine. "
FT Modified-site 23
FΤ
             /note= "opt may have mannose, fucose, glucose or N-Ac-
FT
             glucosamine. "
FT Modified-site 25
FT
             /note= "opt may have mannose, fucose, glucose or N-Ac-
FΤ
             glucosamine. "
FT Modified-site 27
FT
             /note= "opt may have mannose, fucose, glucose or N-Ac-
FT
             glucosamine. "
FT Modified-site 29
FT
             /note= "opt may have mannose, fucose, glucose or N-Ac-
FΤ
             glucosamine. "
FT Modified-site 31
FΤ
             /note= "opt may have mannose, fucose, glucose or N-Ac-
FT
             glucosamine. May also have non interfering substits."
XX
PN WO9219248-A1.
XX
PD 12-NOV-1992.
XX
PF 01-MAY-1992; 92WO-US003609.
XX
PR 03-MAY-1991; 91US-00694983.
XX
PA (UNIW) UNIV WASHINGTON.
XX
PI Stahl PD:
XX
DR WPI; 1992-398516/48.
XX
PT New high affinity mannose receptor ligand cpds. - for treating diseases
PT mediated by macrophage activity e.g. asthma, inflammatory diseases and
PT infectious diseases, e.g. HIV.
```

XX

```
PS Claim 3; Page 21; 32pp; English.
XX
CC This compound represents a glycopeptide effective in inhibiting the
CC binding of labelled mannosylated BSA to mannose receptors. Mannose
CC receptors are uniquely found on macrophages and not on monocytes.
CC Glycopeptides such as this provide a mechanism to target macrophages
CC specifically, to image, label, destroy or otherwise alter their antigen
CC processing function. In addition they can be conjugated to solid supports
CC and used to purify mannose receptors from a variety of sources. They are
CC useful in the treatment of inflammatory diseases driven by macrophage
CC secretory products eg. Crohn's disease; infectious diseases in which
CC macrophages harbour replicating infectious agents eg. lLegionnaires
CC disease; viral infections involving mononuclear phagocytes eg. HIV and
CC lysosomal storage diseases, in which macrophages are principally involved
CC eg. Gaucher's disease; asthma mediated by alveolar macrophages; and in
CC controlling metastasis, mediated by systemic macrophages. The peptides
CC can also be used to deliver antigenic peptides as conjugates to a
CC macrophage to marshal an immune response; also self peptides to prevent
CC tissue transplant rejection. (Updated on 25-MAR-2003 to correct PN
CC field.)
XX
SO Sequence 31 AA:
 Ouerv Match
                     6.3%: Score 18: DB 2: Length 31:
 Best Local Similarity 100.0%; Pred. No. 3.1e-09;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

97 KPKPKPKPKPKPKPKPKP 114

Ov

Dh